Health News Roundup: Wegovy Usage, Bird Flu Concerns, and Legal Actions Shake Pharma World

The health sector is witnessing various noteworthy developments. Analysis shows most U.S. patients stop using Wegovy or Ozempic within two years. Michigan's bird flu measures incite COVID-era worries among farmers. Senator Sanders pressures Novo Nordisk for price cuts. Gerresheimer's deals forecast profits, while Pfizer advances its weight-loss pill. Legal actions and FDA decisions impact big pharma.

Following is a summary of current health news briefs.

An analysis reveals that only one in four U.S. patients continue using Novo Nordisk’s Wegovy or Ozempic for weight loss after two years. The reasons for discontinuation remain unclear, but it highlights the real-world usage beyond short-term studies.

Concerns reminiscent of the COVID-19 pandemic have surfaced among Michigan dairy farmers as the state steps up measures to control bird flu. The regulations, which include farm visitor tracking, are causing anxiety over potential financial impacts in rural areas.

Senator Bernie Sanders is optimistic about pressuring Novo Nordisk to lower the U.S. prices of its weight-loss drugs, Wegovy and Ozempic, by publicly highlighting price discrepancies with other countries. Novo Nordisk’s CEO will testify in an upcoming Senate hearing.

Gerresheimer, a medical equipment group, reported a second-quarter profit driven by its deal pipeline for supplying weight-loss drug makers like Novo Nordisk. The firm expects substantial revenue growth from these deals in the next three years.

In pharmaceutical advancements, Pfizer is moving a new, once-daily version of its weight-loss pill danuglipron into clinical trials, which could offer an alternative to injectable treatments.

The FTC plans to sue major drug middlemen—UnitedHealth, Cigna, and CVS Health—over insulin pricing tactics, scrutinizing their role in rebate negotiations and drug accessibility.